HC Wainwright Issues Positive Forecast for Axsome Therapeutics (NASDAQ:AXSM) Stock Price

Axsome Therapeutics (NASDAQ:AXSM) had its target price lifted by HC Wainwright from $190.00 to $200.00 in a report published on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also recently issued reports on AXSM. Royal Bank of Canada upped their price objective on Axsome Therapeutics from $143.00 to $192.00 and gave the stock an “outperform” rating in a report on Wednesday. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday. Wells Fargo & Company boosted their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Finally, Truist Financial increased their target price on shares of Axsome Therapeutics from $190.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.47.

Axsome Therapeutics Trading Up 1.7 %

Shares of Axsome Therapeutics stock opened at $129.15 on Thursday. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $134.18. The firm has a market cap of $6.26 billion, a PE ratio of -21.56 and a beta of 1.05. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The company has a 50 day simple moving average of $100.34 and a two-hundred day simple moving average of $94.46.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 195.76%. The company had revenue of $118.77 million during the quarter, compared to the consensus estimate of $117.83 million. Analysts expect that Axsome Therapeutics will post -2.26 earnings per share for the current fiscal year.

Insider Transactions at Axsome Therapeutics

In other news, CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 22.40% of the stock is currently owned by company insiders.

Institutional Trading of Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. Raiffeisen Bank International AG bought a new position in Axsome Therapeutics in the 4th quarter worth $51,000. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics during the fourth quarter valued at about $52,000. R Squared Ltd bought a new position in Axsome Therapeutics in the fourth quarter worth about $64,000. Aquatic Capital Management LLC purchased a new stake in Axsome Therapeutics in the fourth quarter worth about $76,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Axsome Therapeutics in the fourth quarter worth about $86,000. Institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.